Attendee search 

Advances in synthetic chemistry and drug screening techniques have flooded the pharmaceutical industry with potential new drugs. At the same time, industry consolidation and financial pressures on R&D budgets have reduced the ability of biotech and pharmaceutical companies to develop early stage drugs. As a result of these market forces, large pharmaceutical companies have restricted their drug development activities to "blockbuster" drugs ($1 billion revenues) with proven efficacy. Promising early-stage drugs developed in emerging biotech and pharmaceutical companies, and university research laboratories are being shelved. 
VDDI Pharmaceuticals has been formed to capitalize on these opportunities. The Company will license attractive product development opportunities from academic institutions, biotech firms and pharmaceutical companies. VDDI Pharmaceuticals will focus on pharmaceutical product opportunities where general proof-of-principle has already been established in pre-clinical or human testing, and where the products are novel and offer significant potential advantages to products currently in the market or in development. VDDI Pharmaceuticals will pursue early-stage products qualifying for fast track approval, primarily in the areas of cancer, cardiovascular disease and infectious disease and develop the products through Phase II of the required regulatory approval processes. The developed products will be licensed to existing pharmaceutical companies for product marketing, thereby generating license fees and ongoing royalties for VDDI Pharmaceuticals.

As its name suggests, VDDI Pharmaceuticals utilizes a virtual business model. Virtual drug development entails: (i) a small core group of employees responsible for strategic management, regulatory strategy, and financial control, (ii) outsourcing all non-core business functions, including preclinical and clinical drug development, and (iii) electronic data capture and data submission to regulatory authorities. By adopting this model, VDDI Pharmaceuticals believes it can reduce total drug development program costs by at least 25% and development times by up to 50%.

Z-Cube invests strategically in technologies that benefit Zambon’s pharmaceuticals and API chemical businesses. 

Within the therapeutics sector, Z-Cube is interested in new technological platforms that enable Zambon’s therapeutic innovation (Z-Cube does not make developmental-stage investments in new chemical entities, and as Zambon only markets small molecule therapeutics, technologies related to biologics are not of interest). This includes drug delivery innovations, and other enabling technologies for therapeutics that do not have to undergo the full therapeutic approval process in order to reach the marketplace. 

Z-Cube is also interested in diagnostics, particularly point of care diagnostics, companion diagnostics and other diagnostics that are used alongside a therapeutic intervention, and diagnostics that can be used in preventative care or to lower overall healthcare costs. Zambon is also interested in diagnostic technologies used to monitor a chronic condition. 

Zambon’s therapeutic focus areas are respiratory diseases and pain (particularly chronic pain), and the firm is also interested in CNS disorders and women’s health (encompassing osteoporosis and rheumatoid arthritis in addition to ob/gyn). However in the diagnostics sector, Zambon is interested in all indications. 

Zambon is additionally interested in digital technologies that enhance communication in the healthcare space, particularly between doctor and patient or between general practitioners and specialists. This includes EMR and telehealth technologies, and devices that transmit information wirelessly. 

Zambon is also interested in innovations in high-tech chemistry, including purification of APIs, advanced crystallography, and novel custom synthesis.

Fusion Genomics Corp (FG) is a molecular diagnostic test  development company that is introducing diagnostic kits with companion analysis software that offer superior clinical information, faster turn-around-times and ease of use for hospitals and clinical laboratories. Fusion is the first of two companies in the world to bring a validated Next Generation Sequencing (NGS) diagnostic test complete with highly secure cloud based analytical service for childhood cancers (ChildSeq-RNA SRCT) into the clinic. This test was validated in the renowned medical testing facility at the Texas Children Hospital, Baylor College of Medicine.

FG is completing development of kits for facilitating absolute diagnosis of pediatric and adult blood cancers. In addition, FG has partnered with the Royal Tropical Institute (Dutch: Koninklijk Instituut voor de Tropen; KIT) a World Health Organization reference diagnostic laboratory for infectious diseases to design the next generation of assays for the detection of infectious diseases including drug-resistant forms of tuberculosis, influenza, hepatitis and hemorrhagic fevers including Ebola.

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.

Precision NanoSystems Inc. (“PNI”) has developed proprietary technology (NanoAssemblr) and companion Reagent Kits (SUB9KITS) that enable the simple manufacture of novel nanoparticles that are used to delivery genetic and small molecule medicines (nanomedicines). Nanomedicines are the "FedEx" of the health-care industry and are used for cell-specific delivery of research tools, diagnostic imaging agents and drugs to study, diagnose and treat disease. PNI's products are commercialized and in high demand from many of leading RNA and small molecule therapeutic biotechnology and pharmaceutical companies.  http://www.precisionnanosystems.com/products/